Mirum Pharmaceuticals Inc (MIRM)
Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals
Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak business signals • Minimal market impact **Sentiment:** Neutral (50%) **Content type:** Business